Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Barter

Showing results (91-100 of 390) with videos related to

Pageof 39
Sort By:
Atherosclerosis|January 1, 1989
Apolipoprotein A-I inhibits transformation of high density lipoprotein subpopulations during incubation of human plasmaG J Hopkins, P J Barter
Journal of Lipid Research|December 1, 1986
Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteinsG J Hopkins, P J Barter
Biochimica Et Biophysica Acta|June 14, 1985
Reactivity of human lipoproteins with purified lecithin: cholesterol acyltransferase during incubations in vitroO V Rajaram, P J Barter
Comparative Biochemistry and Physiology. B, Comparative Biochemistry|January 1, 1986
Effects of sucrose feeding and injection of lipid transfer protein on rat plasma lipoproteinsY C Ha, P J Barter
Osteoarthritis and Cartilage|December 25, 2019
Osteoarthritis year in review 2019: genetics, genomics and epigeneticsL N Reynard, M J Barter
Arteriosclerosis, Thrombosis, and Vascular Biology|February 6, 2016
Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead--ProPhilip J Barter, Kerry-Anne Rye
Clinical Therapeutics|November 10, 2015
Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?Philip J Barter, Kerry-Anne Rye
Journal of the American College of Cardiology|February 7, 2006
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular diseasePhilip J Barter, John J P Kastelein
Osteoarthritis and Cartilage|January 28, 2012
Epigenetic mechanisms in cartilage and osteoarthritis: DNA methylation, histone modifications and microRNAsM J Barter, C Bui, D A Young
Journal of Lipid Research|September 18, 2015
Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?Philip J Barter, Fatiha Tabet, Kerry-Anne Rye
Pageof 39

Showing results (91-100 of 390) with videos related to

Sort By:
Pageof 39
Atherosclerosis|January 1, 1989
Apolipoprotein A-I inhibits transformation of high density lipoprotein subpopulations during incubation of human plasmaG J Hopkins, P J Barter
Journal of Lipid Research|December 1, 1986
Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteinsG J Hopkins, P J Barter
Biochimica Et Biophysica Acta|June 14, 1985
Reactivity of human lipoproteins with purified lecithin: cholesterol acyltransferase during incubations in vitroO V Rajaram, P J Barter
Comparative Biochemistry and Physiology. B, Comparative Biochemistry|January 1, 1986
Effects of sucrose feeding and injection of lipid transfer protein on rat plasma lipoproteinsY C Ha, P J Barter
Osteoarthritis and Cartilage|December 25, 2019
Osteoarthritis year in review 2019: genetics, genomics and epigeneticsL N Reynard, M J Barter
Arteriosclerosis, Thrombosis, and Vascular Biology|February 6, 2016
Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead--ProPhilip J Barter, Kerry-Anne Rye
Clinical Therapeutics|November 10, 2015
Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?Philip J Barter, Kerry-Anne Rye
Journal of the American College of Cardiology|February 7, 2006
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular diseasePhilip J Barter, John J P Kastelein
Osteoarthritis and Cartilage|January 28, 2012
Epigenetic mechanisms in cartilage and osteoarthritis: DNA methylation, histone modifications and microRNAsM J Barter, C Bui, D A Young
Journal of Lipid Research|September 18, 2015
Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?Philip J Barter, Fatiha Tabet, Kerry-Anne Rye
Pageof 39